
Northwestern Medicine investigators have identified distinct T-cell responses associated with patient outcomes in unvaccinated individuals with severe SARS-CoV-2 pneumonia, according to findings published in Nature Immunology.

The surge in RSV cases following the COVID-19 pandemic may have been, in part, caused by increased testing and changes to the RSV genome, according to a Northwestern Medicine study published in Nature Communications.

Scientists have developed a machine-learning approach to track the evolution of the COVID-19 virus and potentially others, according to a study published in the Proceedings of the National Academy of Sciences.

U.S. adults with certain socio-demographic and clinical characteristics may have weaker antibody responses to COVID-19 vaccination, according to a recent study published in Nature Communications.

Testing performance of rapid antigen tests for SARS-CoV-2 improved for both asymptomatic and symptomatic patients after testing multiple times in 48-hour intervals, according to findings published in the Annals of Internal Medicine.

Metformin, a drug commonly used to treat diabetes, may prevent the development of “long COVID,” according to a clinical trial published in The Lancet Infectious Diseases.

A novel protein developed by Northwestern Medicine investigators improved survival and prevented brain infection in mice infected with SARS-CoV-2 when administered intranasally, according to a recent study.

Secondary bacterial pneumonia that did not resolve was a key driver of death in patients with COVID-19, according to a recent study in the Journal of Clinical Investigation.

A new Northwestern Medicine study shows antibodies generated by prior vaccinations or infections can actually “hurt” subsequent COVID-19 booster shots.

Northwestern Medicine investigators continue to study the impact of the COVID-19 pandemic on health outcomes and society, from maternal vaccinations and antibody response to reducing burnout amongst healthcare workers and identifying novel therapeutic targets.